Table 3.
Multivariate analysis for overall survival
| Odds ratio | 95% CI | P value | |
|---|---|---|---|
| Age | |||
| > 45 yrvs. ≤ 45 yr | 4.15 | (1.7–9.9) | 0.001 |
| Gender | |||
| Femalevs. male | 0.65 | (0.4–1.05) | 0.08 |
| Histotype | |||
| c-PTCvs. FV-PTC | 1.09 | (0.5–2.5) | 0.84 |
| TCV-PTCvs.-FV-PTC | 1.63 | (0.6–4.5) | 0.3 |
| FTCvs. FV-PTC | 0.82 | (0.3–2.1) | 0.68 |
| HCCvs. FV-PTC | 1.9 | (0.5–7.3) | 0.3 |
| PDTCvs. FV-PTC | 1.3 | (0.6–2.5) | 1.3 |
| Othersvs. FV-PTC | 1.9 | (0.6–6.3) | 0.3 |
| Presence of bone metastasis | |||
| Not presentvs. present | 0.8 | (0.5–1.3) | 0.3 |
| Preparation | |||
| THW onlyvs. rhTSH only | 0.7 | (0.3–1.5) | 0.4 |
| THS onlyvs. Initial THW followed by rhTSH | 0.8 | (0.5–1.5) | 0.5 |
CI, Confidence interval; PTC, papillary thyroid carcinoma; c-PTC, classical PTC; FV, follicular variant; TCV, tall cell variant; FTC, follicular thyroid carcinoma; HCC, Hürthle cell carcinoma; PDTC, poorly differentiated thyroid carcinoma.